Blossom Health raises $20 million to deploy AI copilot technology across psychiatry practices

Blossom Health raises $20 million to put AI copilots alongside psychiatrists

Blossom Health, a New York-based telepsychiatry startup founded in 2024, has raised $20 million in combined seed and Series A funding to scale an AI-powered platform that pairs psychiatrists with clinical copilots and automated administrative support. The round was led by Headline, whose co-founder and managing partner Mathias Schilling is joining the company's board. Village Global and TA Ventures returned from earlier rounds, with Operator Partners and Correlation Ventures joining as new institutional backers alongside angel investors including founders from General Catalyst, Flatiron Health, Sword Health, and Zip. The company, founded by CEO John Zhao, is built around a specific premise: that the bottleneck in psychiatric care is not a shortage of clinical knowledge but a shortage of time. Psychiatrists in the United States spend roughly half their working hours on non-clinical tasks, including documentation, billing, insurance authorisation, and scheduling. Blossom's platform automates much of this through a network of AI agents that handle billing, reception, care coordination, and medical scribing, while a separate set of clinical copilots assist with symptom evaluation, diagnosis refinement, and medication selection during patient encounters. The psychiatric workforce shortage in the United States is severe and worsening. More than 122 million Americans live in federally designated mental health professional shortage areas, according to the Health Resources and Services Administration. The national psychiatrist-to-population ratio stands at one provider for every 5,058 residents. Roughly 60 per cent of practising psychiatrists are 55 or older, meaning a significant portion of the existing workforce will retire within the next decade. Wait times for an initial psychiatric appointment range from three weeks to six months depending on location, and in many rural counties there are no psychiatrists at all. This gap has created a market. US digital health startups raised $14.2 billion in 2025, the highest total since 2022, with AI-powered companies accounting for 54 per cent of that funding. Within mental health specifically, Talkiatry, an in-network telepsychiatry platform, raised $210 million in February 2026. Spring Health, which uses AI for personalised treatment recommendations, is valued at $3.3 billion. Ambient clinical scribes, the category of AI that automatically generates notes from patient conversations, produced $600 million in revenue last year alone. Blossom is small by comparison. The company says its tools are used by hundreds of clinicians treating more than 10,000 patients across multiple US states. Most patients are seen within 48 hours, with many receiving same-day appointments. Blossom accepts all major commercial insurers, including Optum UnitedHealthcare, Aetna, Cigna Evernorth, and Blue Cross Blue Shield, with average copays of around $22. The "copilot" framing is deliberate and important. Blossom is not building a therapy chatbot. Its AI tools sit alongside licensed psychiatrists during clinical encounters, surfacing relevant information, helping evaluate symptoms against diagnostic criteria, and suggesting medication adjustments based on the patient's history and current presentation. The psychiatrist retains clinical authority over every decision. Between appointments, the platform uses AI agents to maintain contact with patients through text-based check-ins on sleep, mood, medication adherence, and other indicators. Fortune reported that in the case of postpartum depression, for example, the system follows up with conversational prompts that surface warning signs and prepare information for clinicians ahead of the next visit. This approach converts what has traditionally been episodic care, where a patient sees a psychiatrist for 15 minutes every few months and is otherwise unsupported, into something closer to continuous monitoring. The clinical claims are plausible but early. Blossom says it has demonstrated the ability to stabilise mental health conditions and prevent progression toward more intensive care, but the company has not published peer-reviewed clinical evidence. At 10,000 patients, the dataset is meaningful for a company this young but far too small to draw population-level conclusions about clinical efficacy. Any startup operating at the intersection of AI, telepsychiatry, and controlled substance prescribing inherits the reputational burden of what came before. Cerebral, the telemental health company that raised $300 million at a $4.8 billion valuation in 2022, became the subject of a Department of Justice investigation into its prescribing practices for controlled substances and paid a $7 million settlement to the Federal Trade Commission over allegations of misleading cancellation policies and data sharing. The company's rapid growth, which prioritised patient volume over clinical rigour, damaged trust across the sector. Blossom's architecture is different in important ways. It works through licensed psychiatrists rather than nurse practitioners prescribing independently, and its AI tools are positioned as decision support rather than decision-makers. But the fundamental tension remains: scaling psychiatric care through technology requires maintaining clinical quality at volumes that a traditional practice model was never designed to handle. The AI copilot must be good enough to genuinely assist clinicians without introducing errors that a time-pressed psychiatrist might not catch, particularly in medication selection, where psychiatric pharmacology is notoriously complex and highly individual. The $20 million will fund expansion into additional US states, new insurance partnerships, clinician recruitment, and continued research and development. For a company founded less than two years ago, treating over 10,000 patients with in-network insurance coverage is a notable operational achievement. Whether the clinical copilot meaningfully improves outcomes, or simply makes it faster to deliver care at the same quality, is the question the next round of funding will need to answer.

Exclusive: Blossom Health raises $20 million to bring an AI 'copilot' to psychiatry | Fortune

Blossom Health has raised $20 million in seed and Series A funding to bring an AI "copilot" for psychiatry to patients nationwide, Fortune has exclusively learned. The announcement comes as venture dollars have largely chased more generic AI plays, but as investors have increasingly begun to fund AI enabled health tech. The New York-based startup is positioning itself as an AI‑native psychiatry platform, arguing that the technology finally makes it possible to scale high‑quality mental health care without flooding clinics with more staff. The round, led by Headline with participation from Village Global, TA Ventures, Operator Partners, and Correlation Ventures, also adds Headline cofounder Mathias Schilling to the board. "We've been very intentional and disciplined around capital raising," founder and CEO John Zhao told Fortune, noting that all of Blossom's rounds were oversubscribed but that the company "could raise more, but we choose not to." Capital, he added, "is both a weapon and a liability." Zhao, who previously worked at two hyperscale startups -- Athelas, now a multibillion‑dollar company, and online insurance marketplace EverQuote, which he helped scale through an IPO -- frames Blossom as a chance to build a "generational company" in mental health. "As long as there are human beings, we're going to need healthcare, and mental health is only a larger and larger component of each person's holistic health," he said. Blossom's timing, he sees as a counterpoint to the perception that digital mental health has already been solved by the last wave of teletherapy and telehealth platforms. Those platforms, Zhao described as "ill‑equipped or nonexistent" in the psychiatry space. Blossom markets itself as an "all‑in‑one AI copilot" that both augments psychiatrists' clinical decisions and automates the back office tasks that typically bog down an in‑network practice. That means turning what Zhao describes as historically "extremely episodic" care into a continuous relationship driven by AI agents that text patients between visits, help surface warning signs, and tee up information for clinicians. He pointed to a postpartum depression case, where instead of waiting a month until the next visit, Blossom follows up with conversational check‑ins on sleep and mood, "just like texting a therapist," rather than relying on static questionnaires. In general, most patients on the platform are seen in under 48 hours, oftentimes same-day. Zhao is blunt that AI in health care will only work if clinicians buy in. "It starts with listening to clinicians -- and not just listening, but involving them in the creation of all our AI products every step of the way," he said, noting that Blossom's clinical director and "100‑plus clinicians" pilot features before they roll out more broadly. He draws a sharp line between clinical tools and support agents, however. "These are ways we help clinicians treat patients more confidently, accurately, and effectively," Zhao told Fortune. Everything else -- billing, scheduling, dealing with insurers and pharmacies -- is handled by agents that replace what he describes as the "army of people" it used to take to run a clinic. Blossom says its tools are already used by hundreds of clinicians treating more than 10,000 patients across multiple states, and it markets in‑network coverage with major insurers and average copays around $22. The company pitches itself against a backdrop in which roughly one in four U.S. adults experience a mental health condition in a given year, and more than 28 million adults with mental illness receive no treatment at all. Zhao's ambition is to turn Blossom into the "destination of choice" in psychiatry, analogous to a JPMorgan Chase in retail banking, with concrete plans to expand well beyond the nine states it currently serves in the near future, deepen payer relationships, and keep investing in applied AI R&D. "Previously, scale was something that broke healthcare companies," Zhao said. "Now we've flipped that paradigm on its head. The more we grow, the better we are at helping our doctors and helping